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Background. Inadequate treatment practices with antimalarials are considered major contributors to Plasmodium falciparum
resistance to chloroquine, pyrimethamine and sulfadoxine. The longitudinal survey conducted in Dielmo, a rural Senegalese
community, offers a unique frame to explore the impact of strictly controlled and quantified antimalarial use for diagnosed
malaria on drug resistance. Methodology/Principal Findings. We conducted on a yearly basis a retrospective survey over
a ten-year period that included two successive treatment policies, namely quinine during 1990–1994, and chloroquine (CQ)
and sulfadoxine/pyrimethamine (SP) as first and second line treatments, respectively, during 1995–1999. Molecular beacon-
based genotyping, gene sequencing and microsatellite analysis showed a low prevalence of Pfcrt and Pfdhfr-ts resistance
alleles of Southeast Asian origin by the end of 1994 and their effective dissemination within one year of CQ and SP
implementation. The Pfcrt resistant allele rose from 9% to 46% prevalence during the first year of CQ reintroduction, i.e., after
a mean of 1.66 CQ treatment courses/person/year. The Pfdhfr-ts triple mutant rose from 0% to 20% by end 1996, after a mean
of 0.35 SP treatment courses/person in a 16-month period. Both resistance alleles were observed at a younger age than all
other alleles. Their spreading was associated with enhanced in vitro resistance and rapidly translated in an increased incidence
of clinical malaria episodes during the early post-treatment period. Conclusion/Significance. In such a highly endemic
setting, selection of drug-resistant parasites took a single year after drug implementation, resulting in a rapid progression of
the incidence of clinical malaria during the early post-treatment period. Controlled antimalarial use at the community level did
not prevent dissemination of resistance haplotypes. This data pleads against reintroduction of CQ in places where resistant
allele frequency has dropped to a very low level after CQ use has been discontinued, unless drastic measures are put in place
to prevent selection and spreading of mutants during the post-treatment period.
Citation: Noranate N, Durand R, Tall A, Marrama L, Spiegel A, et al (2007) Rapid Dissemination of Plasmodium falciparum Drug Resistance Despite
Strictly Controlled Antimalarial Use. PLoS ONE 2(1): e139. doi:10.1371/journal.pone.0000139
INTRODUCTION
The steady increase of Plasmodium falciparum resistance to cheap
first line antimalarials over the last decades has resulted in
a dramatic increase in malaria-associated morbidity and mortality
in sub-Saharan Africa [1,2]. Research in recent years has
established that resistance to chloroquine (CQ), pyrimethamine
(P) or sulfadoxine (S) results from the accumulation of multiple
mutations in the respective target gene, which once formed, spread
across vast, continent-wide areas [3,4,5,6,7,8]. The conditions
involved in the positive selection of resistant parasites, and the
selective pressure contributing to their spread are largely un-
known. Malpractice in drug usage is unanimously blamed for
permitting emergence of drug resistance, but its impact subsequent
spreading of resistance is not known. One reason is the difficulty
associated with the assessment of drug intake in endemic areas. Anti-
malarial drug pressure is usually inferred from the amount of the
drugpurchasedanddistributedinthecountry,buthowthisrelatesto
the actual selective forces exerted on the parasite population is
unclear, especially since use of antimalarials for any type of fever and
often with non optimal drug regimens is widespread [9].
Previous studies have attempted to correlate parasite resistance
with antimalarials use at the community level, but even in carefully
surveyed settings, irregular compliance and uncertain regimens
precluded definitive conclusions [10,11,12]. The longitudinal
active case detection study launched in Dielmo in 1990, a rural
Senegalese village [13], is probably the only place where drug use
has been controlled and constantly monitored for more than
a decade, coinciding to the time period of expansion of CQ- and
SP-resistance across Africa. This is an unprecedented opportunity
to quantify the impact of a strictly controlled use of antimalarials
on drug resistance. Furthermore, first line treatment was changed
in 1995, allowing to explore its consequences on dynamics of
spreading of drug resistance.
The design of the Dielmo project involves daily medical
surveillance with active case detection, associated with prompt
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ing of medication on an individual basis together with the
longitudinal recording of transmission [13,14,15,16,17]. CQ was
used in the village as presumptive treatment before the onset of the
study, but was replaced by a 3 or 7-day quinine course as first line
treatment of all microscopically diagnosed malaria episodes for the
first five years of the project [13,15,17]. Treatment policy was
modified in 1995, with CQ and the sulfadoxine/pyrimethamine
combination (SP) being used as first and second line treatments,
respectively. Throughout the 1990–9 time period, every treatment
course was recorded and clinical efficacy measured by daily
monitoring. Parasite isolates were collected on a longitudinal basis.
The impact of drug pressure on clinical efficacy, in vitro susceptibi-
lity and drug target gene flow can thus be accurately quantified.
CQ-resistance in vivo has been associated with the presence of
a single point mutation at codon 76 (K76T) of the P. falciparum
chloroquine transporter (Pfcrt) [7,18]. SP-resistance results from
point mutations of the target enzyme dihydrofolate reductase
(DHFR) and dihydropteroate synthase (DHPS), respectively.
Several Pfdhfr-ts mutations have been associated with in vitro
pyrimethamine-resistance, with a key S108N polymorphism that
confers in vitro-resistance [19,20]. Concordant results indicate an
association of the triple N51I C59R S108N Pfdhfr-ts mutant with
reduced therapeutic efficacy [5,21]. Similarly, several Pfdhps
mutations have been associated with decreased susceptibility to
sulfadoxine in vitro. SP therapeutic failures have been associated
with presence of the double A437G, K540E mutant associated
with the Pfdhfr-ts triple mutant [22,23].
We have analysed here the Pfcrt, Pfdhfr-ts and Pfdhps loci in
a panel of clinical isolates collected every year from 1990 to 1999.
We show here that switching to CQ and SP use in 1995 was
followed within a few months by a sharp increase in the prevalence
of resistance haplotypes, pointing to a remarkably rapid expansion
of mutant haplotypes under strictly controlled drug usage. This
was associated with a concomitant increase of in vitro resistance and
with a progressively increased risk of early subsequent clinical
malaria episode after a CQ treatment course.
MATERIALS AND METHODS
Study site and design of the survey
Dielmo, located in Sine Saloum, Senegal, is a village of
approximately 300 inhabitants, where malaria is holoendemic.
Malaria transmission in Dielmo occurs all over the year, unlike the
neighbouring villages where it is highly seasonal. In 1990, the
entire village population was enrolled in a longitudinal prospective
study described in detail elsewhere [13]. Among the population
(female: male ratio=0.98), 20.4% were children less than five
years old and 26.8% were 5–14 year-old children. Individual
informed consent was obtained from each adult participant and
from the parents or legal guardians of all children at the beginning
of the study and was renewed on a yearly basis. Any individual
could withdraw from the study at any time. Each year the project
was reviewed and approved by the Joint Ministry of Health and
Pasteur Institute Surveillance Committee [13,15,17].
From the end of May 1990 onwards, clinical malaria episodes
were diagnosed on site by microscopic examination of blood
smears collected for each febrile episode, and prompt anti-malarial
treatment administered by a medical team present permanently in
the village, who subsequently monitored therapeutic and parasi-
tological efficacy [13,14,15,17].The population of Dielmo was
asked not to use any drug without informing the medical team.
Random urine tests were made on a regular basis to detect the
presence of antimalarials [15]. This indicated the remarkable
compliance of the villagers with the study design and anti-malarial
intake. For each malarial episode, a fingerpick or 2 mL venous
blood sample was collected and stored as a frozen red blood cell
pellet at 280uC.
The study period explored here was 29 May 1990–31 Dec
1999. The intensity of malaria transmission was determined by
weekly or monthly mosquito collections as described [13]. During
this period, the entomological inoculation rate fluctuated from 115
to 347 infective bites/person/year, depending on the year.
Anti-malarial use
Before the longitudinal survey, CQ was irregularly used as the
presumptive treatment, together with traditional medicines.
Measures of CQ levels in children were made before the onset
of the project using the Bergquist test. This showed that about
13% of the children had detectable CQ levels, similar to children
from five neighbouring villages. From 29 May 1990 to 17 Jan
1995, quinine (QuinimaxH) administered every 8hr by a medical
field worker or a physician for 3 or 7 days was used for 96.4% of
the 1722 anti-malarial treatments administered, including a total
of 277 eradication therapies in 1992 and 1994 [24,25]. Halofan-
trine was used for eradication therapy in 46 adults in 1994 and
CQ for three curative treatments, representing 3.42% and 0.17%
of anti-malarial treatments administered, respectively. Early in
1995, the treatment policy was changed to CQ (NivaquineH), and
SP (FansidarH) as first and second line treatments, respectively
[17]. CQ was introduced on 20 Jan 1995, and SP was used for the
first time on 12 Sep 1995. From 01 Jan 1995 to 31 Dec 1999
quinine, CQ and SP were used for 5.2%, 85.3% and 9.5% of the
3130 anti-malarial treatments administered, respectively. There
was no chemoprophylaxis among villagers. The use of antimalar-
ials was restricted to acute malaria attacks in accordance with the
following criteria: 1) fever with a parasite:leukocyte ratio #2i n
children less than 10 years of age, 2) fever with a parasite:leukocyte
ratio #0.5 in pregnant women, or 3) fever with a positive thick
blood film in individuals with symptoms compatible with severe
malaria or in individuals returning from an area of low endemicity
where they had lived for more than one year during the past three
years. When fever persisted the next day, another thick blood film
was made. Criteria for antimalarials treatment remained un-
changed. However, in the absence of any clinical improvement
associated with a parasite density close to the treatment threshold
in children and adults, or a positive thick blood smear in pregnant
women, the prescription of a second antimalarial treatment was
based on the patient’s clinical and epidemiological data.
The yearly intake of antimalarials, which represents drug
pressure on the local parasite population, is depicted in Figure 1.
We used each calendar year, except for the year 1990 which
included the period 29 May–31
st Dec 1990. The lack of non-
prescribed CQ use by villagers in 1990–94 was ascertained by
consistently negative random monthly urine tests [13,15,17]. The
number of CQ and SP treatments per person per year was
calculated based on the number of days of follow up divided by the
number of persons enrolled that year. These were as follows :
51,745/253, 81,120/235, 82,583/238, 90,761/263, 89,551/260,
88,908/257, 100,706/293; 95,917/289, 100,942/299, 99,083/
298 for 1990 (7 months of follow up), 1991, 1992, 1993, 1994,
1995, 1996, 1997, 1998, 1999, respectively.
In vivo efficacy
The risk of early occurrence of a subsequent clinical malaria
episode after a CQ or SP treatment course was estimated by the
proportion of cases present in the village for $31 days after the
Antimalarial Drug Resistance
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or 28 days by a second P. falciparum high density episode or the
need to administer an additional antimalarial treatment. From 1.1
to 7.7% of the treatments were administered for P. ovale clinical
attacks. None necessitated a second treatment course. They were
counted in the overall number of antimalarial treatments
administered, but not in the calculation of risk of subsequent
clinical malaria episodes that was restricted to P. falciparum attacks.
Overall, there were 1899 first CQ treatment courses for which
the clinical follow-up was complete for the next 7, 14, 21 and 28
days. There were 127, 316, 587 and 812 second treatments
administered within ,7, 14, 21 and 28 days, respectively. The 199
SP treatment courses administered all had a complete follow-up
for .31 days. There were 5, 6, 16 and 48 cases of administration
of another treatment within 7, 14, 21 and 28 days, respectively.
The protocol for the longitudinal follow up was not designed as
a drug clinical trial, and parasite clearance was not systematically
recorded as recommended for trials. The detailed analysis of
therapeutic efficacy over this decade using additional criteria
(including clearance rates when available and incorporating
individual host risk factors, age patterns as well as fluctuations of
transmission) is in progress and will be reported elsewhere (Tall et
al, in preparation).
Parasite population surveyed
Since the parasites exposed to heavy drug pressure were those
associated with clinical episodes, we studied parasites collected
during clinical malaria attacks. The isolates were selected from the
existing collection of frozen blood samples as follows: we
interrogated the database to identify the samples collected before
treatment administration from patients diagnosed with a clinical
malaria episode (fever+high parasite density) over the 10 y-period.
From a list of approx 3400, 336 samples were chosen for
molecular analysis so as to survey the largest possible panel of
villagers, but ignoring therapeutic efficacy of the treatment
administered after sample collection, and selecting wherever
possible isolates with interpretable in vitro data, whatever the result
of the assay. Since in this holoendemic setting, the heaviest clinical
malaria burden is in the ,10 y olds and since furthermore some
children are more susceptible than others [16], we needed to avoid
iteration biases due to increased susceptibility of some individuals.
We therefore set a $three y interval between two samples from the
same individual and set the additional restriction that no person
could contribute with more than three samples overall. This
reduced the risk of over-representing certain genotypes to which
some individuals might be more susceptible than others, and also
of over-estimating polymorphism because successive clinical
malaria attacks experienced by one person are caused by ‘‘novel’’
parasites [26].
The number of isolates studied each year is shown in Table 1.
The samples originated from 246 villagers, with 167, 68 and 11
villagers contributing once, twice and three times, respectively, to
the panel of isolates for the retrospective molecular survey. There
were 130 males and 116 females among the villagers recruited
[175 and 161 males and females, respectively, among the panel of
isolates studied]. The mean age at the time of blood sampling was
11.4613.1 years. The isolates were from 31 out of 34 village
compounds.
In vitro susceptibility assays
Venous blood samples were collected during the high transmission
season on a longitudinal basis from consenting patients with
clinical malaria. Assays were conducted using the isotopic
microtest as described [27,28,29] on clinical malaria isolates
collected in the village or in the health centre of Toubacouta. The
isolates with an IC50 .100 nM and .2000 nM for CQ and
pyrimethamine, respectively, were classified as resistant
[27,28,29].
DNA extraction
Frozen blood samples were thawed and extracted with phenol-
chloroform as described [30] and stored at 220uC until use.
Figure 1. Amount of antimalarials used in Dielmo from 1990 to 1999.
The mean number of person-years surveyed was 124 in 1990 (from June to December) and 295, 235, 238, 262.8, 260.1, 257.1, 292.5, 288.7, 299.3 and
297.8 from 1991 to 1999, respectively. The cumulated survey days were 51745, 81120, 82583, 90761, 89551, 88908, 100706, 95917, 100942 and 99083
from 1990 to 1999, respectively. The monthly quinine, CQ and SP intake was calculated from the recorded drug prescriptions in the data base. For
,5% of cases, the actual prescribed dose was not available and was extrapolated from the standard treatment course at that time in the village. The
peaks in 1992 and 1994 correspond to eradication therapies administered to 100, 118, and 59 persons, respectively [21,22]. There were 155, 262, 567,
310, 428, 435, 710, 649, 681 and 823 treatment courses administered from 1990 to 1999, respectively.
doi:10.1371/journal.pone.0000139.g001
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Molecular beacons for Pfdhfr108 and Pfcrt76 genotyping were
used essentially as described [31,32]. The PCR primer and
molecular beacon sequences are shown in Table S1. The
molecular beacons reliably detect $10% of the alternative
genotype. However, in the samples used here the ratio of allele
was not greater than 1/3.
Gene sequencing
Gene sequencing was carried out for the isolates typed by
molecular beacons as containing a single allelic form at the locus.
All sequence data with ambiguous positions were rejected. The 72-
6/220 Pfcrt gene sequence was established as described [33], using
the primers listed in Table S1. The entire 1.8 kb Pfdhfr-ts coding
sequence was amplified by PCR in a 50 mL reaction volume
containing 2 mL DNA, 10 mM Tris-HCl pH 9.0 at 25uC, 50 mM
KCl, 0.1% Triton X-100, 2.5 mM MgCl2, 200 mM each dNTP,
0.6 mM each DhfrPfQs and DhfrPfCoasQ primers (see Table S1),
with 2.5 U Taq Polymerase (Promega). After an initial de-
naturation step at 94uC for 3 min, samples were subjected to 5
cycles of denaturation at 94uC for 30 sec and hybridization/
extension at 64uC for 4 min followed by 35 cycles of denaturation
at 94uC for 10 sec and hybridization/extension at 66uC for 3 min
15 sec, with a final extension step for 8 min. The amplified PCR
products were visualized on an 1.5% agarose gel by ethidium
bromide staining. A second PCR was performed on the negative
samples in a 50 mL volume as above, using 2 mL of the first
reaction and 0.8 mM each of dhfrsm13 and dhfrasm13 primers
(see Table S1). The nested PCR conditions were: an initial
denaturation step at 94uC for 3 min 94uC followed by 25 cycles of
denaturation at 94uC for 30 sec and hybridization/extension at
66uC for 4 min, with a final extension for 10 min at 66uC. Direct
sequencing was done with forward and reverse external and
internal sequencing primers (see Table S1 for primer sequence),
using an ABI Prism sequencer 3100 as described [34].
The complete coding region of Pfdhps was amplified and
sequenced (ABI 3100 Genetic Analyser, Applied Biosystems,
Courtaboeuf, France) as described [23].
Pfmsp1 block2 genotyping
The highly polymorphic Pfmsp1 block 2 was typed by semi-nested
PCR in a 50 mL reaction volume containing 5 mL DNA, 50 mM
KCl, 1.5 mM MgCl2, 10 mM Tris-HCl pH 9.0, 200 mM dNTP,
5 U Taq Polymerase (Amersham Pharmacia), 1 mM of each
primer (see Table S1 for primer sequence). For the first PCR, a first
denaturation step at 96uC for 5 min was used, followed by 25
cycles of denaturation at 96uC for 1 min; hybridization at 64uC for
1.30 min, extension at 72uC for 45 sec with a final extension at
72uC for 7 min. The semi-nested PCR was carried out using
a forward family specific primer and a reverse conserved primer
(see Table S1), under the same conditions except that annealing
was done at 68uC. PCR products were analysed on 1.5%
Nusieve:agarose gels (1:3). The size of the bands was evaluated
using the 100 bp DNA ladder (BioRad) as size markers. Alleles
were classified in 10 bp bins.
Microsatellite genotyping
Microsatellites were determined from single genotype infections
from which we had obtained reliable unambiguous gene sequence
at all positions. All ambiguous results were rejected from the
analysis. The Pfcrt intron 4 microsatellite was analysed by direct
sequencing of the PCR fragment generated using primers located
within exons 4 and 5 (see primer sequence in Table S1) essentially
as described [33]. The various Pfcrt intron 4 microsatellite types
were assigned codes described in Table S2.
The Pfdhfr-ts flanking microsatellite loci called 20.1 kb, and
+0.5 kb, as well as for some isolates the 24.4 kb locus, were
studied by semi-nested PCR using specific primers described by
Roper et al 2003 [5] and Nair et al, 2003 [35] (primer sequences
shown in Table S1) but using different experimental conditions as
follows. The primary and secondary mixture reactions for the
20.1 kb and 24.4 kb loci were carried out in a 50 mL reaction
volume containing 10 mM Tris-HCl pH 9.0, 50 mM KCl,
0.1%TritonHX-100, 2.5 mM MgCl2, 0.64 mM dNTP, 0.05 U
Taq polymerase (Promega) and 1 mM each primer. The reactions
were cycled as follows: denaturation at 95uC for 5 min, followed
by 35 cycles of denaturation at 95uC for 30 sec, annealing at 58uC
for 45 sec and extension at 72uC for 30 sec, followed by a final
extension at 72uC for 7 min, then held at 4uC. The fluorescent
labelled primer was added in the secondary reaction using the
same reaction cycles. For the +0.5 kb locus, the primary and
secondary PCR were done as above except that MgCl2 was used at
1.5 mM and that annealing was done at 48uC for the first reaction
and at 53uC for the secondary PCR. For microsatellite genotyping,
1 mL of diluted PCR products was added to 10 mLo f
a formamide/ROX-labeled internal size standard (GenescanH
400HD [ROX], Applied Biosystems) mixture (82:1), then
processed on an ABI Prism 3700 automated DNA sequencer for
electrophoresis. Data were imported to GeneScan software to
perform fragment analysis by sizing each peak relative to the
internal standard. The results were imported to Genotyper
software to provide final results in allele calls as well as automated
table building. Reference fragments from 3D7 and FCC1 were
included as standards in each amplification experiment. The 3D7
and FCC1 Pfdhfr-ts haplotypes are described in Table S3.
Statistical analysis
Allelic frequencies and multiplicity of infection were compared by
the exact Fisher and Kruskall-Wallis tests, respectively. We first
considered each calendar year separately and subsequently
grouped together consecutive years that were not statistically
different. The temporal Pfcrt genotype distribution could be
Table 1. Number of isolates studied by calendar year of survey
and successfully typed by molecular beacons for the Pfcrt
K76T and Pfdhfr-ts S108N loci and by nested PCR for the
Pfmsp1 block2 locus.
......................................................................
No isolates typed
No isolates
studied Pfcrt Pfdhfr msp1block 2
year of
survey (N=336) (N=324) (N=303) (N=306)
1990 23 23 22 23
1991 30 30 30 29
1992 30 29 29 29
1993 37 37 36 36
1994 35 32 30 34
1995 38 35 34 33
1996 46 44 41 38
1997 26 24 18 25
1998 52 51 44 44
1999 19 19 19 15
doi:10.1371/journal.pone.0000139.t001
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and 1995–9. The temporal Pfdhfr-ts genotype distribution showed
four distinct periods namely1990–92, 1993–4, 1995 and 1996–9.
Mean and median age distribution by Pfcrt or Pfdhfr-ts genotype
were analysed by the Kruskall-Wallis test. Genetic diversity was
assessed by the number of alleles per locus and Nei’s unbiased
expected heterozygosity (He) [36] from haploid data using FSTAT
version 2.9.4. (Goudet J. (2003) update from [37]). Differences
between the estimated He at each locus were tested by the
Wilcoxon signed rank test using STATA 9 software (Stata
Corporation, College Station, TX, USA). The selection coefficient
(s) was calculated as described by Nair et al [35] from the slope
obtained by plotting Ln(R/S), with R and S being the frequency of
the resistant and sensitive allele, respectively, against the number
of estimated parasite generations. For CQ-selection, R and S were
calculated from the K76T Pfcrt molecular beacon genotype based
on prevalence of infected individuals for each allele. S, which
indicates the relative survival of resistant and sensitive parasites at
each generation, was calculated using two estimates for parasite
generation, namely 2 or 4 months i.e. 6 to 3 generations per year
[38]. The fitness (f) of resistant parasites was estimated by w=1+s.
Linkage disequilibrium was tested using GENEPOP V3.3 [39].
The null hypothesis was the independence of the genotypes at one
locus from genotypes at the other locus. GENEPOP creates
contingency tables for all pairs of loci in each period, then
performs a probability test (or Fisher’s exact test) for each table
using a Markov chain [40]. The frequencies of early occurrence of
a subsequent clinical malaria episodes after an anti-malarial
treatment were compared using exact Fisher’s tests.
RESULTS
Resistance mutation frequency assessed by
molecular beacons
The Pfcrt K76T and Pfdhfr-ts S108N genotypes, which are key to
resistance to CQ and pyrimethamine, respectively, were estab-
lished for 324 isolates (151 from 1990–1994 and 173 from 1995–
1999) and 303 isolates (147 from 1990–1994 and 156 from 1995–
1999), respectively. The K76 and 76T Pfcrt genotypes were
detected in 269 and 100 isolates, respectively. The wild type S108
and mutant 108N Pfdhfr-ts were detected in 259 and 67 isolates,
respectively. Multiple infections, i.e. infections where both mutant
and wild type codons were present, accounted overall for 14% (45
of 324) and 7.6% (23 of 303) of the isolates for Pfcrt and Pfdhfr-ts,
respectively. The average number of alleles per isolate did not vary
for the Pfcrt locus over the 10y period (Kruskall-Wallis test,
p=0.18) (Figure 2A). In contrast, it showed significant temporal
variations for the Pfdhfr-ts locus (Kruskall-Wallis test p=0.001,
Fisher’s exact test, p=0.001) (Figure 2A).
The Pfcrt allele distribution varied significantly over time. The
proportion of isolates harbouring a mutant 76T (either single or
associated with the K76 allele) decreased from approx. 22% in
1990–92 to 8.7% in 1993–94, increased to 44% in 1995 and
subsequently remained at a similarly elevated level (Fisher’s exact
test, p=0.004 and ,0.001, respectively) (Figure 2B). Thus, the
change for CQ in 1995 was followed by a marked increase in the
prevalence of the mutant allele. It was also associated with an
augmented prevalence of isolates containing the 76T mutant type
only, which raised from 4.3% in 1993–94 to 29.5% in 1995–99
(Fisher’s exact test, p,0.001; Figure 2C). During the year 1995,
the selection coefficient of the 76T mutants was 0.22 and 0.44,
assuming 3 and 6 generations/year, respectively.
The frequency of mutant 108N Pfdhfr-ts genotypes (either single
or in multiple infections) decreased from 18.5% in 1990–92 to 3%
in 1993–94 (Fisher’s exact test, p=0.021), increased to 20% in
1995 and again to around 35% in 1996–99 (Fisher’s exact test,
p,0.001) (Figure 2B). This increase was associated with an
increasing proportion of isolates typed as containing only the 108N
mutant that increased from 1.5% in 1993–94 to 11.8% in 1995
(Fisher’s exact test, p=0.043) and further increased to 30.3% in
1996–99 (Fisher’s exact test, p=0.030) (Figure 2C). Thus, in
1990–94, the 108N mutation was detected mainly in mixed
infections, whereas it was present mostly in isolates containing that
single allele in 1995–99.
Multiplicity of infection
To test whether drug policy has impacted on the overall
multiplicity of infection, we genotyped Pfmsp1 block 2, a highly
polymorphic locus derived from a merozoite surface antigen,
unrelated to the CQ or SP target genes and frequently used for
assessing multiplicity of infection [26,30]. Pfmsp1 block2 genotypes
were established for 306 isolates. This highlighted 38–66%
multiple infections, depending on the year. The mean number
of distinct Pfmsp1 block2 alleles detected for each isolate did not
show significant fluctuation over the years (Kruskall-Wallis test,
p=0.51) (Figure 2A). This indicated that the various drug
regimens implemented in the village throughout the 10y period
did not profoundly affect the average number of parasite clonal
types associated with clinical malaria.
Genotyping by direct sequencing
To look for the presence of additional mutations in the target
genes and establish haplotypes, we sequenced PCR-amplified gene
fragments or full length genes. For Pfcrt, we analysed the gene
region coding for the resistance haplotype, where the 76T
mutation is associated with additional 74I 75E mutations also
encoded by exon 2, together with a 220S mutation encoded by
exon 4 [7]. The 74-76/220 haplotype was determined for 21
isolates with a 76T mutation by amplification and sequencing. All
isolates harboured the CVIET/S haplotype. No novel mutation
was observed in this region (data not shown).
A 1827 bp Pfdhfr-ts full gene sequence was generated for 204
isolates (91 from 1990–1994 and 113 from 1995–1999). This
identified three previously reported single nucleotide polymorph-
isms [SNP] (51I, 59R and 108N) and four novel SNPs within the
Pfdhfr-ts coding region [59Y, and two synonymous L40L and one
G241G]. The ts coding region was identical in all samples. Overall
there were nine distinct alleles at the nucleotide level, including
four wild type alleles, three of which with synonymous substitu-
tions. Hence at the protein level, there were six distinct alleles: wild
type, single mutant (51I or 59Y or 108N), double mutant (51I
108N) and triple mutant (51I 59R 108N) alleles. It is noteworthy
that the 59R SNP was not detected as a single or double mutant,
but was observed only in the triple mutant haplotype. Their
temporal distribution is shown in Figure 3. There was no
significant increase of any single mutant after SP introduction in
the village in 1995. However, the 51I 59R 108N triple mutant
frequency increased from 1.1% in 1990–94 to 15.4% in 1995 and
further increased to 32.2% in 1996–1999 (Fisher’s exact test,
p,0.001).
Analysis of Pfdhps by sequencing was done for 27 isolates
collected in 1997–1999. This identified one S436F (3.7%), one
S436A (3.7%) and 9 A437G (33%) mutants. The other positions,
including codon 540 usually associated with SP-resistance [22]
were wild type. All alleles sequenced were single mutants (data not
shown). So, overall there were four distinct Pfdhps alleles detected
in this analysis.
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mutants using microsatellite genotyping
To analyse the genetic relatedness of the alleles carrying the
CVIET/S haplotype, we sequenced the exon4-exon5 Pfcrt gene
region encompassing the intron 4 microsatellite, located just
downstream from codon 220 [3,7]. This was done for 247 isolates.
No novel mutation was detected in the exons. Thirty one
microsatellite types were observed. Their distribution was highly
skewed (Skewness-kurtosis tests for normality, p,0.001) (Figure 4).
All but one CVIET/S alleles were associated with a type 13
microsatellite [(TAAA)3(TA)15], i.e. presented the characteristic
intragenic signature of the resistance allele of Southeast Asian
origin [33]. One CVIET/S allele was associated with the related
type 14 microsatellite [(TAAA)3(TA)16] (unbiased expected
heterozygosity He=0.07, n=31). In contrast, the CVMNK/A
Figure 2. Temporal variation of the multiplicity of infection in Dielmo (A), frequency of Pfcrt codon 76 and Pfdhfr-ts codon 108 genotypes (B)
and frequency of infections with only mutant type detected (C). The number of isolates typed at each locus is indicated in Table 1.
(A). Multiplicity of infection is depicted separately for each locus. For Pfmsp1 block2, the figures derive from nested PCR analysis using family-specific
primers and allele identification based on allelic family assignment and size polymorphism. For Pfcrt and Pfdfhr-ts, it is based on K76T and S108N
genotypes determined by molecular beacons, respectively. Symbols used: (Red triangles): Pfcrt codon 76 genotype; (green squares): Pfdhr-ts codon
108 genotype, (blue open circles) Pfmsp1 block2.
B) Allelic frequency of resistance genotypes, calculated as percentage of mutant genotype within the total number of alleles detected for each locus.
Symbols used as in A.
C) Percentage of isolates containing only the mutant type. Symbols used as in A.
doi:10.1371/journal.pone.0000139.g002
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microsatellite types (Table S2), depending on the isolate (unbiased
expected heterozygosity He=0.93, n=318).
To study Pfdhfr-ts gene flow within the village, flanking
microsatellites were analysed. We typed 81 isolates for the
20.1 kb and +0.5 kb microsatellite loci, including 38 for the
additional 24.4 kb microsatellite locus (Figure 5 and Table S3).
This showed that the Pfdhfr-ts wild type coding sequence was
associated with 41 distinct microsatellite combinations. Each
microsatellite locus was highly polymorphic [unbiased expected
heterozygosity He=0.88, 0.89 and 1.00, n=73, 62 and 5 for the
20.1, +0.5 and 24.4 kb loci, respectively. Heterozygosity across
the three loci (mean6SD)=0.8860.01]). There were a minimum
of three distinct haplotypes for the 108N single mutants [for three
108N mutants, the +0.5 kb microsatellite could not be determined,
but each had a different 20.1 kb/24.4 kb microsatellite haplo-
type] and each of the single 51I and 51I 108N double mutants was
associated with a distinct microsatellite combination [heterozygos-
ity across the three loci for the single or double mutants
(mean6SD)=0.8260.1]). In contrast, all 51I 59R 108N triple
mutants were associated with a single microsatellite allele at each
locus [He=0.00, 0.00 and 0.00, N=16, 15 and 26 for the 20.1,
+0.5 and 24.4 kb, respectively, heterozygosity across the three
loci: (mean6SD)=0.0060.00]. Thus, there was a single tri-
microsatellite locus haplotype associated with the Pfdhfr-ts triple
mutant. This resistance haplotype is most likely the same as the
resistance allele of Southeast Asian origin described in KwaZulu
Natal and Tanzania in 1995–9 [5,6], since they have microsatellite
profiles that can be regarded as identical, considering inter-
laboratory experimental differences inherent to microsatellite
typing.
There was no significant linkage disequilibrium between Pfcrt
and the Pfdhfr-ts coding sequence and/or flanking microsatellites
(Fisher’s exact test, each p-value .0.00119, i.e. the adjusted p-
value for 5% nominal level). As predicted and confirming the
above analysis, Pfdhfr-ts and its flanking microsatellites were in
strong linkage disequilibrium (Fisher’s exact test, p=0.00024 for
each pair of loci)
Allele distribution by age
While there was no influence of blood group or gender on Pfcrt
and Pfdhfr-ts allele distribution, there was an influence of age.
Table 2 shows that isolates with only the Pfcrt 76T mutation
detected were from younger individuals than those with the wild
type K76 allele or those containing both K76+76T mutations
(Kruskall-Wallis test; Chi-squared=6.28 with 2 d.f., p=0.043).
The Pfdhfr-ts allele distribution was also age-associated, with the
triple mutant detected at a younger age than the wild type, single
and double mutants (Kruskall-Wallis test; Chi-squared=6.7 with 2
d.f., p=0.035). The S108N genotype distribution showed no
association with age (p=0.283).
Drug pressure and selection of resistance
Figure 6 A shows the temporal increase of resistance vis-a `-vis CQ
pressure in the village. During year 1995, 404 CQ treatment
courses were administered, corresponding to 1.66 treatment/
person/year. During the following years, there was an average of
2.16 CQ courses/person/year and overall 2,345 CQ treatment
courses in 1996–9. In vitro susceptibility was assessed sporadically
over 1990–4 and systematically over a few month period at the
end of each calendar year over 1995–9. In vitro resistance to CQ,
which was low (3.8%) over 1990–4 was markedly increased by the
end of 1995, and fluctuated around 45–50% thereafter. The
temporal variation of in vitro resistance to CQ paralleled the
prevalence of Pfcrt ‘‘76T only’’ infections. The clinical impact of
Figure 3. Temporal variation of the relative Pfdhfr-ts gene polymorphism in Dielmo during 1990–99.
The 1.8 kb PCR fragment corresponding to the full length Pfdhfr-ts coding sequence was sequenced on both strands for a total of 204 isolates. The
yearly distribution of the various genotypes is shown, using the colour code shown to the right of the figure. The alleles presenting synonymous
mutations were omitted from the colour coding.
The C59Y non-synonymous substitution was a TGT to TAT mutation. The synonymous mutations (CTA to TTA or CTC for codon 40, GGA to GGC for
codon 241) are not depicted. No mutation was detected at codon 16 and 164, and no bolivia repeat type was observed. Overall there were 155
isolates with wild type coding sequence and 49 isolates with non synonymous mutations (76% and 24%, respectively). There were 15 (7.3%) single
mutants [51I (0.5%), 59Y (1%), 108N (5.8%)], one (0.5%) 51I 108N double mutant and 33 (16.2%) 51I 59R 108N triple mutants.
doi:10.1371/journal.pone.0000139.g003
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a second treatment course within the ,7, 14, 21 and 28 days after
the end of the treatment. Occurrence of clinical malaria episodes
within 7 days of CQ treatment progressively increased with
increasing cumulative number of CQ treatments in the village,
resulting in a 5 fold increase in 1999 compared to 1995 (Fisher’s
Exact test, p,0.001). Such a regular increase was not observed for
the longer follow-up periods, nevertheless the incidence of second
episodes within 14 days of CQ treatment was doubled in 1999
compared to 1995 (Fisher’s Exact test, p,0.001), and it was
increased by 1.67- and 1.41-fold by 21 and 28 days, respectively
(Fisher’s Exact test p,0.001 each). The prevalence of episodes
within 14 days and more markedly within 21 and 28 days
paralleled the prevalence of the isolates with only the Pfcrt 76T
mutant (Figure 6A).
The temporal increase of resistance vis-a `-vis SP pressure is
shown in Figure 6B. The number of SP treatments/person/year
increased from 0.07 in 1995 to 0.5 in 1998–9, corresponding
overall to 424 SP treatments administered in the village during
1995–9, and a mean of 0.31 treatments/person/year. In vitro
resistance to pyrimethamine progressively raised from 14% in
1995 to 50% in 1998 and 1999 with increasing pressure
(Figure 6B). There was a strong correlation between the increase
in Pfdhfr-ts triple mutant frequency and the increasing SP drug
pressure during that period (R
2=0.9, with a linear model).
Overall, 75 of 199 SP treatment courses were followed by a second
treatment (5, 6, 16 and 48 within ,7, 14, 21 and 28 days,
respectively). Confidence intervals were wide, due to the small
number of events each year. The occurrence of 2nd treatment
within 21 and 28 days fluctuated between 1996 and 1999 and no
temporal trend could be conclusively established.
Comparison with neighbouring villages
To compare the situation in Dielmo with the surroundings by end
of 1995, CQ-in vitro tests were conducted during the period Oct
1995–mid Jan 1996 in the health centre of Toubacouta, which
captures 11 neighbouring villages with typical CQ-usage. This
showed different proportion (Chi2, p,0.005) and level of
resistance (log transformed ANOVA p,0.05) between the two
sites. In Dielmo, there was approx 60% CQ-resistance (N=43
samples; mean IC50 for CQ=102 nM; 95% CI=72.8–143.4 nM;
min=25 nM, max=563 nM), compared to 24% in Toubacouta
(N=50 samples, mean IC50 for CQ=53.6, 95% CI=43.2–
66.4 nM, min=25 nM, max=261 nM).
DISCUSSION
Here, we have explored whether a strictly controlled use of CQ
and SP, administered for microscopically diagnosed, high density
malaria episodes would prevent spreading of resistance. Our data
indicate that such a drug policy failed to do so. The reintroduction
of CQ after several years of discontinued use was followed by rapid
dissemination of the Pfcrt resistance allele of Southeast Asian origin
and of CQ-resistance in vitro and progressive deterioration of its
clinical efficacy. Within four years of SP introduction in the village
as second line drug, in vitro pyrimethamine-resistance had
markedly raised, Pfdhfr-ts resistance genotypes had reached the
same prevalence as CQ-resistance genotypes and a similar trend
was observed for the A437G Pfdhps mutant.
Figure 4. Frequency distribution of Pfcrt intron 4 microsatellite types by codons 72–76 and 220 haplotype.
247 isolates were typed (19, 23, 22, 33, 28, 22, 29, 17, 39 and 15 isolates in 1990, 1991, 1992, 1993, 1994, 1995, 1996, 1997, 1998 and 1999,
respectively) for the intron 4 microsatellite by gene sequencing (see Materials and Methods). There were 31 CVIETS haplotypes and 216 wild type
haplotypes. The haplotype codes are listed in Table S2.
doi:10.1371/journal.pone.0000139.g004
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person/year) to raise the Pfcrt 76T mutation from a 8–9%
prevalence in 1993–4 to 46% during the year 1995. Increased
pressure (2752 CQ treatments cumulated during the years 1995–9)
did not increase the prevalence of the mutant much further, did
not increase the in vitro resistance further either, but increased by
five-fold the rate of treatment failures within 7 days. It took 112 SP
treatments in the community (Sep–Dec 1995–year 1996) to raise
the prevalence of the triple Pfdhfr-ts mutant from 0% in 1994 to
20% in 1996. The pressure on the parasite population was
altogether strong because of the very high proportion of high
density episodes treated through active medical surveillance and
essentially restricted to the 0–14 y age group who accounted for
47% of the village population and experienced 93% of the clinical
malaria attacks [13,16]. Thus, an overall remarkably limited
number of treatments in a fraction of the population resulted in
massive changes over a very short time period.
The clinical impact of the drug policy implemented in the
village for ten years was evaluated by measuring the need for an
additional treatment during the one month post-treatment period.
The incidence of clinical malaria within 7 days of CQ treatment
raised from 2.6% in the year 1995 to reach 13% in the year 1999.
This represents a marked increase compared to the 1% incidence
by day 7 post-Quinine treatment in the period 1990–3 [41]. These
episodes should therefore be classified as early treatment failures.
The incidence of early treatment failure after CQ implementation
in 1995 increased rapidly, but much slower than the increase of in
vitro resistance and increase in 76T mutant frequency. Increase of
mutant prevalence and/or of in vitro resistance are thus relevant
indicators of emerging therapeutic failures.
Since CQ half-life is 10–30 days, the parasites that reached high
density during the 14–28 day post-treatment period had to survive
sub-therapeutic post-treatment drug levels. The increased in-
cidence of a second episode within 14, 21 and 28 days of a CQ
treatment from 1995 to 1999 correlating with increasing of the
76T Pfcrt mutant frequency is consistent with selection of parasites
(be they recrudescence or re-infection) during the post-treatment
period. The children were administered several treatments each
year [14,16], and consequently had quite substantial post-
Figure 5. Frequency distribution of Pfdhfr-ts 24.4 kb/201 kb+
0.5 kbmicrosatellite haplotypes by coding the sequence mutant
type.
The microsatellites were determined as described in Materials and
Methods for 81 isolates. The haplotype codes are listed in Table S3.
doi:10.1371/journal.pone.0000139.g005
Table 2. Age association of mutant Pfcrt and Pfdhfr-ts
prevalence over the entire survey period.
......................................................................
Pfcrt K Pfcrt K+T Pfcrt T
Total
genotyped
median age (y) 7.6 9.6 4.7 7.0
[25–75] quartile 3–15 5–17 3–8 3–14
min 0.4 0.7 0.3 0.3
max 69.7 42.5 89.7 89.7
No indiv 224 45 55 324
Pfdhfr wt*
Pfdhfr single
& double
mutants
Pfdhfr triple
mutant**
Total
sequenced
median age (y) 7.4 5.9 3.9 6.3
[25–75] quartile 3–11 2–8 3–7 3–11
min 0.4 0.4 0.3 0.3
max 89.7 15.3 38 89.7
No indiv 155 16 33 204
*wt=wild type
**51I 59R 108N
doi:10.1371/journal.pone.0000139.t002
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PLoS ONE | www.plosone.org 9 January 2007 | Issue 1 | e139treatment time periods, providing the terrain for selecting
resistance haplotype among the re-infecting parasites. This is in
line with the observed higher frequency of the resistance allele in
the younger age group. The dark side of the treatment policy used
with properly dosed and administered CQ may thus be to help
spreading of reinfecting parasites with resistant genotypes selected
during the post treatment period.
The SP pressure was substantially lower than that of CQ and
yet similar conclusions can be drawn. There was quite efficient
expansion of in vitro resistance to pyrimethamine associated with
dissemination of the Pfdhfr-ts triple mutant, consistent with its
reported increased transmissibility [42]. The incidence of early
treatment failures was marginal. This is not surprising since SP
therapeutic failures have been associated with presence of the
‘‘quintuple mutant’’, namely the Pfdhfr-ts triple mutant associated
with the Pfdhps A437G K540E double mutant [22,23], which was
not detected in the village. Similar observations were reported for
isolates collected in different localities across Senegal in the years
2000–3 [43,44] This confirms the time shifted invasion by Pfdhfr-ts
and Pfdhps alleles observed in East Africa, with invasion of the
triple mutant Pfdhfr-ts preceding invasion by the Pfdhps double
mutant that is associated with SP-treatment failure [5,23]. The use
of antibiotics such as Sulfamethoxazole+Trimethoprim (Bac-
trim
TM), which may contribute to antifolate resistance [45,46,47]
was restricted in Dielmo, and furthermore did not substantially
vary over the 1990–9 period. This indicates a key role for SP
pressure in antifolate resistance in the village. The only mutant
Pfdhfr-ts genotype that expanded under SP drug pressure had the
typical molecular signature of the ancestral resistance haplotype of
Southeast Asian origin that has spread across Africa [5,6]. Several
Pfdhfr-ts point mutations were detected, including novel ones not
observed in other Senegalese sites [43,44]. None expanded under
SP pressure. Each single mutation was associated with a distinct
microsatellite haplotype. This is consistent with, but by no means
a proof of local generation of mutants. The consequence of the
C59Y mutation on enzyme activity is unknown [48].
There was a considerable slowing down of the invasion process
after an explosive rapid first phase, despite continued drug
pressure. We interpret this as a consequence of having restricted
drug pressure to a fraction of the Dielmo population and hence of
the parasite reservoir. Thus, older children and adults perpetuated
a large parasite population that remained essentially without drug
pressure. It is most likely the combination of efficiently treating
only a fraction of the potential parasite transmitters with the strong
overall population immunity that has slowed down further
spreading of resistant mutants in this setting.
Where do the resistant parasites that disseminated after CQ and
SP implementation come from? Most probably from local
expansion of the residual low frequency resistance alleles and
from invasion of resistant strains from the surroundings. Trans-
Figure 6. Temporal distribution of CQ and SP drug pressure and drug resistance in Dielmo in 1990–9.
The drug pressure is expressed as No of treatments/person/year (first graph) and as overall No of treatment courses administered per year (second
graph). Panels A and B refer to CQ and SP, respectively. The prevalence of the Pfcrt mutant alleles was calculated from molecular beacon studies
(N=324) (see Figure 2), while the prevalence of the Pfdhfr-ts triple mutant was calculated from the full gene sequences available (N=202) (see
Figure 3). In vitro susceptibility assays were carried out in 1990–4 during the rainy season (N=26) and from 1995 onwards for the last 2–3 months of
the year, namely from 7/11/1995–26/12/1995 (N=46) ; 6/01/1996–3/12/1996 (N=59); 27/10/97–15/121997 (N=26) ; 10/01/1998–15/11/1998 (N=54)
and 29/09/1999–08/11/1999 (N=25). The proportion of interpretable CQ and pyrimethamine susceptibility tests was 68–81% and 72–81%,
respectively, depending on the year. The prevalence of resistance is expressed as the percent of interpretable assays presenting a CI50 for CQ
.100 nM or a CI50 for pyrimethamine.2000 nM. The occurrence of a second clinical malaria episode within 7, 14, 21 and 28 days of treatment was
calculated as described in Materials and Methods. The bars correspond to the 95% confidence interval. The years before implementation of CQ and
SP (1990–4) are grouped together.
A. CQ pressure, Pfcrt 76T resistance mutation, CQ in vitro resistance and prevalence of clinical attacks following a CQ treatment
B. SP pressure, Pfdhfr-ts triple mutant, pyrimethamine in vitro resistance and prevalence of clinical attacks following a SP treatment
Colour codes: 1990–4: grey; 1995: purple; 1996: yellow; 1997: light green; 1998: light blue; 1999: orange.
doi:10.1371/journal.pone.0000139.g006
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PLoS ONE | www.plosone.org 10 January 2007 | Issue 1 | e139mission is perennial in Dielmo due to the presence of permanent
mosquito breeding sites [13], unlike the surroundings, where it is
highly seasonal [49]. Based on the entomological inoculation rate,
the villagers’ habits during the mosquito biting time periods and
the geographic distance from breeding sites outside the village, we
estimate that 97% of the infections in adults and 99% of the
infections in young children are contracted within the village. The
surrounding area was certainly infested with CQ-resistance by
1995, as indicated by the in vitro resistance data from the health
centre of Toubacouta. The relative contribution of expansion of
residual alleles from within the village and invasion of alleles from
the neighbourhood during the rainy season is uncertain. Dissection
of the phenomenon requires additional population genetic studies.
The Dielmo unique longitudinal assessment at the community
level during 10 years of clinical malaria incidence, malaria
treatment, drug use, genetics of parasites, travels of individuals,
anopheline density and entomological inoculation rates, provides
the first autopsy of the spread of drug resistance in an African
setting. This indicates that a population unit cannot deter the
rapid spread of CQ- and SP-resistance when resistance alleles are
present (even at low rate) within the village or in the vicinity, and
this even when drug use is strictly reserved for the treatment of
properly diagnosed acute malaria attacks and essentially in
children. This argues against deploying antimalarials in areas
where resistance haplotypes are present, even at low frequency,
unless drastic measures are taken to prevent their spreading.
Recent report that CQ is again efficacious against clinical malaria
in Malawi after discontinued use for more than 1 years has raised
hopes for a future reintroduction of CQ in this country [50,51].
Reintroducing chloroquine is conceivable only once CQ-re-
sistance has totally disappeared or if its transmission is completely
blocked. Neither of these conditions are met. CQ-resistance has
invaded the whole African continent, although it tends to decline
in countries that have discontinued its use [50,52,53]. Using
chloroquine in combination therapy requires a companion drug
that efficiently prevents selection of reinfecting CQ-resistant
parasites during the post-treatment period, otherwise spreading
of CQ resistance will turn the drug combination into mono-
therapy. Artemisinin derivatives reduce gametocyte production
[54] but their a very short half life is unlikely to prevent selection of
re-infecting CQ-resistant parasites during the post-treatment
period. A further important conclusion of our study is that greater
attention should be paid in drug development to design molecules
that target sexual stages as well, and in control efforts to prevent
dissemination of the resistance haplotypes, which once formed,
will have their spreading promoted by drug pressure.
SUPPORTING INFORMATION
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